Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity

Anti-GD2 strategy in the treatment of neuroblastoma

(2014) R.K. Yang et al.   DRUGS OF THE FUTURE

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

(2011) I. N. Buhtoiarov et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc  Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

(2010) D. C. Delgado et al.   CANCER RESEARCH

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome

(2010) Jesús García-Foncillas et al.   Clinical & Translational Oncology

Anti-GD2 Antibody Therapy for GD2-Expressing Tumors

(2010) F. Navid et al.   CURRENT CANCER DRUG TARGETS

Trastuzumab

(2010) Karly P. Garnock-Jones et al.   DRUGS

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

(2010) Suzanne Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment

(2010) Nathalie T. Joncker et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MHC class I–deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I–sufficient environment

(2010) Julie M. Elliott et al.   JOURNAL OF EXPERIMENTAL MEDICINE

'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection

(2010) Mark T Orr et al.   NATURE IMMUNOLOGY

This Week in the Journal

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

(2010) Linda S. Sorkin et al.   PAIN

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

(2009) Shigeru Iida et al.   BMC CANCER

KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma

(2009) J. M. Venstrom et al.   CLINICAL CANCER RESEARCH

Ten years of rituximab in NHL

(2009) Matthew C Winter et al.   Expert Opinion On Drug Safety

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

(2009) Brett H Yamane et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Strength of T Cell Receptor Signal Controls the Polarization of Cytotoxic Machinery to the Immunological Synapse

(2009) Misty R. Jenkins et al.   IMMUNITY

Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma

(2009) David J. Betting et al.   JOURNAL OF IMMUNOTHERAPY

Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies

(2008) W. Lin et al.   BLOOD

Intratumoral immunocytokine treatment results in enhanced antitumor effects

(2008) Erik E. Johnson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

(2008) Alessandra Beano et al.   Journal of Translational Medicine